Angiotensin II receptor activation in youth triggers persistent insulin resistance and hypertensiona legacy effect

Hypertension Research

Volumn 35, Issue 3, 2012, Pages 334-340

  Togashi, Nobuhiko ^a   Maeda, Takuto ^a   Yoshida, Hideaki ^a   Koyama, Masayuki ^a   Tanaka, Marenao ^a   Furuhashi, Masato ^a   Shimamoto, Kazuaki ^a   Miura, Tetsuji ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

angiotensin II; insulin resistance; MCP 1; TNF

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; CANDESARTAN; GLUCOSE; HYDRALAZINE; MONOCYTE CHEMOTACTIC PROTEIN 1; RAC1 PROTEIN; TEMPOL; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DRUG INFUSION; GLUCOSE CLAMP TECHNIQUE; HYPERINSULINEMIA; HYPERTENSION; INFLAMMATION; INFUSION RATE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MOUSE; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; SKELETAL MUSCLE; SOLEUS MUSCLE; SPRAGUE DAWLEY RAT; UPREGULATION;

AGING; ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; BODY WEIGHT; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; HYPERTENSION; INSULIN RESISTANCE; MUSCLE, SKELETAL; RAC1 GTP-BINDING PROTEIN; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RECEPTORS, ANGIOTENSIN; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863230139     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.206     Document Type: Article

References (33)

1. Moan A, Risanger T, Eide I, Kjeldsen SE. The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension. Blood Press 1994; 3: 185-188. (Pubitemid 24169150)
2. Shimamoto K, Matsuda K, Takizawa H, Higashiura K, Ura N, Iimura O. Effects of an angiotensin II receptor antagonist, TCV-116, on insulin sensitivity in fructose-fed rats. Blood Press 1994; 5: S113-S116.
3. Iimura O, Shimamoto K, Matsuda K, Masuda A, Takizawa H, Higashiura K, Miyazaki Y, Hirata A, Ura N, Nakagawa M. Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives. Am J Hypertens 1995; 8: 353-357.
4. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 1997; 100: 2158-2169. (Pubitemid 27500137)
5. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm Jr RH, Messerli FH, Oparil S, Schork MA. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354: 1685-1697.
6. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
7. The Diabetes Control Complications Trial/Epidemiology of Diabetes Interventions Complications (DCCT/EDIC) Study Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
8. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res 2002; 91: 406-413. (Pubitemid 35034208)
9. Takahashi M, Suzuki E, Takeda R, Oba S, Nishimatsu H, Kimura K, Nagano T, Nagai R, Hirata Y. Angiotensin II and tumor necrosis factor-alpha synergistically promote monocyte chemoattractant protein-1 expression: roles of NF-kappaB, p38, and reactive oxygen species. Am J Physiol Heart Circ Physiol 2008; 294: H2879-H2888.
10. Asamizu S, Urakaze M, Kobashi C, Ishiki M, Norel Din AK, Fujisaka S, Kanatani Y, Bukahari A, Senda S, Suzuki H, Yamazaki Y, Iwata M, Usui I, Yamazaki K, Ogawa H, Kobayashi M, Tobe K. Angiotensin II enhances the increase in monocyte chemoattractant protein-1 production induced by tumor necrosis factor-alpha from 3T3-L1 preadipocytes. J Endocrinol 2009; 202: 199-205.
11. Maehaut N, Van de Voorde J. Regulation of vascular tone by adipocytes. BMC Med 2011; 16: 9-25.
12. Togashi N, Ura N, Higashiura K, Murakami H, Shimamoto K. The contribution of skeletal muscle tumor necrosis factor-alpha to insulin resistance and hypertension in fructose-fed rats. J Hypertens 2000; 18: 1605-1610.
13. Wei Y, Sowers JR, Clark SE, Li W, Ferrario CM, Stump CS. Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. Am J Physiol Endocrinol Metab 2007; 294: E345-E351. (Pubitemid 351231460)
14. Polla BS, Cossarizza A. Stress proteins in inflammation. EXS 1996; 77: 375-391.
15. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA 1994; 91: 4854-4858. (Pubitemid 24177748)
16. Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333-336. (Pubitemid 35398190)
17. Wei Y, Whaley-Connell AT, Chen K, Habibi J, Uptergrove GM, Clark SE, Stump CS, Ferrario CM, Sowers JR. NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat. Hypertension 2007; 50: 384-391. (Pubitemid 47205789)
18. Yamaguchi K, Ura N, Murakami H, Togashi N, Hyakukoku M, Higashiura K, Shimamoto K. Olmesartan ameliorates insulin sensitivity by modulating tumor necrosis factor-alpha and cyclic AMP in skeletal muscle. Hypertens Res 2005; 28: 773-778. (Pubitemid 41723537)
19. Bae YS, Lee JH, Choi SH, Kim S, Almazan F, Witztum JL, Miller YI. Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: toll-like receptor 4-and spleen tyrosine kinase-dependent activation of NADPH oxidase 2. Circ Res 2009; 104: 210-218.
20. Moe KT, Yin NO, Naylynn TM, Khairunnisa K, Wutyl MA, Gu Y, Atan MS, Wong MC, Koh TH, Wong P. Nox2 and Nox4 mediate tumor necrosis factor-alpha-induced ventricular remodeling in mice. J Cell Mol Med 2011; in press.
21. Khaper N, Bryan S, Dhingra S, Khaper N, Bryan S, Dhingra S, Singal R, Bajaj A, Pathak CM, Singal PK. Targeting the vicious inflammation-oxidative stress cycle for the management of heart failure. Antioxid Redox Signal 2010; 13: 1033-1049.
22. Banday AA, Lokhandwala MF. Oxidative stress-induced renal angiotensin AT1 receptor upregulation causes increased stimulation of sodium transporters and hypertension. Am J Physiol Renal Physiol 2008; 295: F698-F706.
23. Falkner B, Hulman S, Tannenbaum J, Kushner H. Insulin resistance and blood pressure in young black men. Hypertension 1990; 16: 706-711.
24. Hirata A, Shimamoto K, Masuda A, Miyazaki Y, Fukuoka M, Iimura O. Influence of aging on insulin sensitivity in essential hypertensives and normotensives. Hypertens Res 1995; 18: 307-311. (Pubitemid 26035609)
25. Rahmouni K, Morgan DA, Morgan GA, Liu X, Sigmund CD, Mark AL, Haynes WG. Hypothalamic PI3 kinase and MAP kinase differentially mediate regional sympathoactivation to insulin. J Clin Invest 2004; 114: 652-658. (Pubitemid 39578755)
26. Shimamoto K, Hirata A, Fukuoka M, Higashiura K, Miyazaki Y, Shiiki M, Masuda A, Nakagawa M, Iimura O. Insulin sensitivity of the effects of insulin on renal sodium handling and pressor systems in essential hypertensive patients. Hypertension 1994; 23: S129-S133.
27. Kamide K, Hori MT, Zhu JH, Barrett JD, Eggena P, Tuck ML. Insulin-mediated growth in aortic smooth muscle and the vascular renin-angiotensin system. Hypertension 1998; 32: 482-487. (Pubitemid 28429137)
28. Li Y, Higashiura K, Ura N, Torii T, Agata J, Wang L, Togashi N, Shimamoto K. Effects of the Chinese medicine TSJN on insulin resistance and hypertension in fructose-fed rats. Hypertens Res 2000; 23: 101-107. (Pubitemid 30326233)
29. Dobrian AD, Schriver SD, Khraibi AA, Prewitt RL. Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. Hypertension 2004; 43: 48-56. (Pubitemid 38031910)
30. Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995; 8: 316-320.
31. Lombardi D, Gordon KL, Polinsky P, Suga S, Schwartz SM, Johnson RJ. Salt-sensitive hypertension develops after short-term exposure to angiotensin II. Hypertension 1999; 33: 1013-1019. (Pubitemid 29186401)
32. Paravicini TM, Touyz RM. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care 2008; 32: S170-S180.
33. Wei Y, Sowers JR, Nistala R, Gong H, Uptergrove GM, Clark SE, Morris EM, Szary N, Manrique C, Stump CS. Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. J Biol Chem 2006; 281: 35137-35146. (Pubitemid 46036553)